Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
April 17 2023 - 7:00AM
Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage
biotechnology company developing induced pluripotent stem cell
(iPSC)-derived cell therapies in immuno-oncology, today announced
that Greg Russotti, Ph.D., ad-interim Chief Executive Officer, will
participate in a fireside chat at Chardan’s 7th Annual Genetic
Medicines & Cell Therapy Manufacturing Virtual Summit on
Monday, April 24, 2023 at 10:30 AM ET.
A replay of the event will be available on the “Events &
Presentations” page in the “Investors” section of the Company’s
website
at https://investors.centurytx.com/events-and-presentations
and will be available for 30 days following the events.
About Century Therapeutics
Century Therapeutics, Inc. (NASDAQ: IPSC) is a clinical-stage
biotechnology company harnessing the power of adult stem cells to
develop curative cell therapy products for cancer that we believe
will allow us to overcome the limitations of first-generation cell
therapies. Our genetically engineered, iPSC-derived iNK and iT cell
product candidates are designed to specifically target hematologic
and solid tumor cancers. We are leveraging our expertise in
cellular reprogramming, genetic engineering, and manufacturing to
develop therapies with the potential to overcome many of the
challenges inherent to cell therapy and provide a significant
advantage over existing cell therapy technologies. We believe our
commitment to developing off-the-shelf cell therapies will expand
patient access and provide an unparalleled opportunity to advance
the course of cancer care. For more information on Century
Therapeutics please visit https://www.centurytx.com/.
Century Therapeutics Forward-Looking
Statement
This press release contains forward-looking statements within
the meaning of, and made pursuant to the safe harbor provisions of,
The Private Securities Litigation Reform Act of 1995. All
statements contained in this press release, other than statements
of historical facts or statements that relate to present facts or
current conditions, including but not limited to, statements
regarding our clinical development plans and timelines, are
forward-looking statements. These statements involve known and
unknown risks, uncertainties and other important factors that may
cause our actual results, performance, or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. In some cases, you can identify forward-looking
statements by terms such as “may,” “might,” “will,” “should,”
“expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “forecast,” “potential” or “continue” or the negative of
these terms or other similar expressions. The forward-looking
statements in this press release are only predictions. We have
based these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our business, financial
condition, and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions, some
of which cannot be predicted or quantified and some of which are
beyond our control, including, among others: our ability to
successfully advance our current and future product candidates
through development activities, preclinical studies, and clinical
trials; our ability to obtain FDA acceptance for our future IND
submissions and commence clinical trials on expected timelines, or
at all; our reliance on the maintenance of certain key
collaborative relationships for the manufacturing and development
of our product candidates; the timing, scope and likelihood of
regulatory filings and approvals, including final regulatory
approval of our product candidates; the impact of the COVID-19
pandemic, geopolitical issues and inflation on our business and
operations, supply chain and labor force; the performance of third
parties in connection with the development of our product
candidates, including third parties conducting our future clinical
trials as well as third-party suppliers and manufacturers; our
ability to successfully commercialize our product candidates and
develop sales and marketing capabilities, if our product candidates
are approved; and our ability to maintain and successfully enforce
adequate intellectual property protection. These and other risks
and uncertainties are described more fully in the “Risk Factors”
section of our most recent filings with the Securities and Exchange
Commission and available at www.sec.gov. You should not rely on
these forward-looking statements as predictions of future events.
The events and circumstances reflected in our forward-looking
statements may not be achieved or occur, and actual results could
differ materially from those projected in the forward-looking
statements. Moreover, we operate in a dynamic industry and economy.
New risk factors and uncertainties may emerge from time to time,
and it is not possible for management to predict all risk factors
and uncertainties that we may face. Except as required by
applicable law, we do not plan to publicly update or revise any
forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or
otherwise.
For More Information: Company: Elizabeth
Krutoholow – investor.relations@centurytx.comInvestors/Media:
Melissa Forst/Maghan Meyers – century@argotpartners.com
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Century Therapeutics (NASDAQ:IPSC)
Historical Stock Chart
From Sep 2023 to Sep 2024